Home Stock

Stock Research: Mayne Pharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Mayne Pharma

ASX:MYX AU000000MYX0
69
  • Value
    96
  • Growth
    1
  • Safety
    Safety
    48
  • Combined
    49
  • Sentiment
    94
  • 360° View
    360° View
    69
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Mayne Pharma Group Limited is a specialty pharmaceutical company. It operates in Women’s Health, Dermatology, and International segments and distributes products like NEXTSTELLIS and ANNOVERA. The company operates in the United States and Australia. In the last fiscal year, the company had a market cap of $267 million, profits of $151 million, and revenue of $264 million.

more

ANALYSIS: With an Obermatt 360° View of 69 (better than 69% compared with alternatives), overall professional sentiment and financial characteristics for the stock Mayne Pharma are above average. The 360° View is based on consolidating four consolidated indicators, with half the metrics below and half above average for Mayne Pharma. The consolidated Value Rank has an attractive rank of 96, which means that the share price of Mayne Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 96% of alternative stocks in the same industry. The consolidated Sentiment Rank has a good rank of 94, which means that professional investors are more optimistic about the stock than for 94% of alternative investment opportunities. But the consolidated Growth Rank has a low rank of 1, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. The consolidated Safety Rank has a riskier rank of 48, meaning the company has a riskier financing structure than 52 comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Growth
Weakest Rank Analyst Opinions
Country Australia
Industry Pharmaceuticals
Size Small
Website maynepharma.com
Index
ASX 300
Mayne Pharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
96 40 54 89
Growth
1 84 75 49
Safety
Safety
48 33 53 24
Sentiment
94 40 86 20
360° View
360° View
69 47 92 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
100 60 22 57
Opinions Change
50 50 100 50
Pro Holdings
n/a 1 78 24
Market Pulse
43 69 70 25
Sentiment
94 40 86 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
96 40 54 89
Growth
1 84 75 49
Safety Safety
48 33 53 24
Combined
49 55 71 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
95 82 87 93
Price vs. Earnings (P/E)
91 86 86 24
Price vs. Book (P/B)
100 59 75 95
Dividend Yield
1 1 1 100
Value
96 40 54 89
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
1 71 80 93
Profit Growth
6 72 4 1
Capital Growth
1 56 50 71
Stock Returns
3 70 99 31
Growth
1 84 75 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
79 59 65 22
Refinancing
51 58 83 77
Liquidity
18 4 8 8
Safety Safety
48 33 53 24

Similar Stocks

Discover high‑ranked alternatives to Mayne Pharma and broaden your portfolio horizons.

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

West African Resources

ASX:WAF
Country: Australia
Industry: Gold Production
Size: Medium
Full Stock Analysis

Ono Pharmaceutical

TYO:4528
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Nippon Shinyaku

TYO:4516
Country: Japan
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

With good value and positive sentiment, but low growth and risky financing, this combination is generally dangerous as debt requires growth to sustain it. Only investors with a strong belief in future growth potential and a high-risk tolerance should consider this stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews